Abstract:Abstract Background Recent studies reporting the intricate crosstalk between cellular and molecular mediators and the lymphatic endothelium in the development of inflammatory bowel diseases (IBD) suggest altered inflammatory cell drainage and lymphatic vasculature, implicating the lymphatic system as a player in the occurrence, development, and recurrence of intestinal diseases. This article aims to review recent data on the modulatory functions of cellular and molecular components of the IBD microenvironment on the lymphatic system, particularly lymphangiogenesis. It serves as a promising therapeutic target for IBD management and treatment. The interaction with gut microbiota is also explored. Main text Evidence shows that cells of the innate and adaptive immune system and certain non-immune cells participate in the complex processes of inflammatory-induced lymphangiogenesis through the secretion of a wide spectrum of molecular factors, which vary greatly among the various cells. Lymphangiogenesis enhances lymphatic fluid drainage, hence reduced infiltration of immunomodulatory cells and associated-inflammatory cytokines. Interestingly, some of the cellular mediators, including mast cells, neutrophils, basophils, monocytes, and lymphatic endothelial cells (LECs), are a source of lymphangiogenic molecules, and a target as they express specific receptors for lymphangiogenic factors. Conclusion The effective target of lymphangiogenesis is expected to provide novel therapeutic interventions for intestinal inflammatory conditions, including IBD, through both immune and non-immune cells and based on cellular and molecular mechanisms of lymphangiogenesis that facilitate inflammation resolution.

Inflammatory bowel disease and angiogenic factor

Updated Correlation Between Angiopoietic Factors and Inflammatory Bowel Disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Angiocrine Regulation of Epithelial Barrier Integrity in Inflammatory Bowel Disease

Chronic Inflammation and Colorectal Cancer: the Role of Vascular Endothelial Growth Factor

The Involvement of Glial Cell-Derived Neurotrophic Factor in Inflammatory Bowel Disease

[Advances in the Research of Mechanisms of Promotion of Vascularization by Angiogenin and Its Application].

Advances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review)

The emerging role of hypoxia and environmental factors in inflammatory bowel disease

Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease

Angiogenesis：molecular mechanism and related diseases

Hypoxia, hypoxia-inducible factors and inflammatory bowel diseases

The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease

The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease

Advances in research on the role of high carbohydrate diet in the process of inflammatory bowel disease (IBD)

Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta‐analysis

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease

Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer

Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota